Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles

Yi Zhao, Daria Y. Alakhova, Xiangshan Zhao, Vimla Band, Elena V. Batrakova, Alexander V. Kabanov

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

The potency of polymeric micelle-based doxorubicin, SP1049C, against cancer stem cells (CSCs) in triple negative breast cancer (TNBC) is evaluated. CSCs with high epithelial specific antigen (ESA), high CD44 and low CD24 expression levels were derived from the TNBC cancer cells, MDA-MB-231 and MDA-MB-468. These CSCs were resistant to free doxorubicin (Dox) and displayed increased colony formation, migration, and invasion in vitro, along with higher tumorigenicity in vivo, compared to the parental and non-CSCs counterparts. SP1049C downregulated the expression and inhibited the functional activity of the breast cancer resistance protein (BCRP/ABCG2) in CSCs. The polymeric micelle drug had higher cytotoxicity and potency in reducing the colony formation of CSCs compared to the free drug. It was also more potent in inhibiting the tumor growth in the orthotopic animal tumor models derived from CSCs. These results indicate that SP1049C is active against CSCs and has potential in treating TNBC.

Original languageEnglish (US)
Article number102124
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume24
DOIs
StatePublished - Feb 2020

Keywords

  • Cancer
  • Cancer stem cells
  • Doxorubicin
  • Drug resistance
  • Pluronic
  • Poloxamer
  • Triple negative breast cancer

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Molecular Medicine
  • Biomedical Engineering
  • Materials Science(all)
  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles'. Together they form a unique fingerprint.

  • Cite this